New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2013
12:27 EDTAMGNEarnings Preview: Amgen shares up sharply in July ahead of Q2 results
Amgen (AMGN) is scheduled to report Q2 earnings after the market close on Tuesday, July 30, with a conference call scheduled for 5:00 pm ET. Amgen is an American-based multinational biopharmaceutical company headquartered in Thousand Oaks, California. EXPECTATIONS: Analysts are looking for EPS of $1.74 on revenue of $4.49B, according to First Call. The consensus range for EPS is $1.66-$1.83 on revenue of $4.35B-$4.57B. LAST QUARTER: Amgen reported Q1 EPS of $1.96 against estimates of $1.84 on revenue of $4.2B, against estimates of $4.37B. STREET RESEARCH: On May 1, Amgen was upgraded to Conviction Buy from Neutral at Goldman. Goldman upgraded Amgen based on valuation and its late-stage pipeline which is highly innovative and has the potential to replace key biologic franchises that are coming off patent. Goldman raised its price target to $130 from $100 on Amgen shares. PRICE ACTION: Amgen shares have rallied approximately 15% since early July and are up 0.9% on the day to $110.35
News For AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
11:36 EDTAMGNRumor: Amgen moves up on speculation of an investor stake
Subscribe for More Information
07:03 EDTAMGNCelgene leaps forward in immuno-oncology with Juno deal, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said that Celgene (CELG) effectively spent $1B to buy into adoptive T cell therapy and own all of Juno Therapeutics' (JUNO) opportunities outside the U.S., leaping the company into a leading position in the immuno-oncology space. Schimmer additionally thinks Celgene's transaction should help boost investor confidence about the utility and value of CAR and TCR therapies, noting that he sees Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), bluebird bio (BLUE) and the Amgen (AMGN)-Kite Pharma (KITE) partnership as best positioned to compete in this rapidly advancing field. The analyst keeps an Overweight rating and $144 price target on Celgene.
June 24, 2015
07:56 EDTAMGNAmgen management to meet with Evercore ISI
Subscribe for More Information
June 23, 2015
07:25 EDTAMGNPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use